Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937176 | 0.83 | SLC9A1 (0.59) | CYP1A2CYP2C19SLC9A1KDM4EKMT2A | |
| SCHEMBL4944299 | 0.82 | S1PR4 (0.51) | SLC9A1KDM4EKMT2AHPGDSMN1; SMN2 | |
| SCHEMBL4942499 | 0.81 | MEN1 (0.53) | SLC9A1KDM4EKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4944763 | 0.80 | MAPKAPK2 (0.52) | CYP1A2CYP2C19SLC9A1KDM4EHPGD | |
| SCHEMBL9877550 | 0.80 | CYP1A2 (0.71) | CYP1A2CYP2C19SLC9A1KDM4EKMT2A | |
| SCHEMBL4936806 | 0.79 | SLC9A1 (0.61) | CYP1A2CYP2C19SLC9A1KDM4EKMT2A | |
| SCHEMBL4943798 | 0.79 | SLC9A1 (0.61) | CYP1A2CYP2C19SLC9A1KDM4EKMT2A | |
| SCHEMBL19657014 | 0.78 | SLC9A1 (0.66) | CYP1A2CYP2C19SLC9A1KDM4EKMT2A | |
| SCHEMBL5842720 | 0.78 | SLC9A1 (0.74) | CYP1A2CYP2C19SLC9A1KDM4EKMT2A | |
| SCHEMBL4936883 | 0.78 | SMN1; SMN2 (0.61) | SLC9A1KDM4EHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351843-B2 | Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-04-01 | — | — | US | disclosed |
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | SLC9A1, NHERF1, SLC5A1 | CYP1A2 1319/4885CYP2C19 403/4885SLC9A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.